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Abstract
Background and Aims: Preparative hepatic irradiation (HIR), together with mitotic stimulation of hepatocytes, permits
extensive hepatic repopulation by transplanted hepatocytes in rats and mice. However, whole liver HIR is associated with
radiation-induced liver disease (RILD), which limits its potential therapeutic application. In clinical experience, restricting HIR
to a fraction of the liver reduces the susceptibility to RILD. Here we test the hypothesis that repopulation of selected liver
lobes by regional HIR should be sufficient to correct some inherited metabolic disorders.
Methods: Hepatocytes (107) isolated from wildtype F344 rats or Wistar-RHA rats were engrafted into the livers of congeneic
dipeptidylpeptidase IV deficient (DPPIV2) rats or uridinediphosphoglucuronateglucuronosyltransferase-1A1-deficient
jaundiced Gunn rats respectively by intrasplenic injection 24 hr after HIR (50 Gy) targeted to the median lobe, or median
plus left liver lobes. An adenovector expressing hepatocyte growth factor (1011 particles) was injected intravenously 24 hr
after transplantation.
Results: Three months after hepatocyte transplantation in DPPIV2 rats, 30–60% of the recipient hepatocytes were replaced
by donor cells in the irradiated lobe, but not in the nonirradiated lobes. In Gunn rats receiving median lobe HIR, serum
bilirubin declined from pretreatment levels of 5.1760.78 mg/dl to 0.9660.30 mg/dl in 8 weeks and remained at this level
throughout the 16 week observation period. A similar effect was observed in the group, receiving median plus left lobe
irradiation.
Conclusions: As little as 20% repopulation of 30% of the liver volume was sufficient to correct hyperbilirubinemia in Gunn
rats, highlighting the potential of regiospecific HIR in hepatocyte transplantation-based therapy of inherited metabolic liver
diseases.
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Introduction
Hepatocyte transplantation has been used as an alternative to
whole liver transplantation for amelioration of metabolic deficien-
cies in a number of patients with various inherited liver-based
metabolic disorders [1–7]. While these studies have demonstrated
the safety and feasibility of this procedure, the number of
hepatocytes that could be engrafted in single procedures was
insufficient for complete cure of these diseases [8–11]. In the
majority of inherited metabolic diseases of the liver, the longevity
of the mutant hepatocytes is not significantly limited. Because the
liver to body weight ratio is tightly regulated by physiological
mechanisms, simple metabolic stimulation does not lead to
extensive proliferation of the donor cells. Inhibition of the mitotic
potential of the host cells provides a competitive proliferative
advantage to the donor cells [12,13], allowing massive prolifera-
tion of the donor cells, which replace significant fractions of the
host hepatocyte mass in response to mitotic stimuli. Since the
chemical methods used by many investigators for this purpose are
probably not suitable for translation to clinical application, we
have explored hepatic irradiation (HIR) to inhibit the growth of
the host hepatocytes [14,15]. Our results in rodent and non-
human primate models show that preparative whole liver HIR
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augments the initial engraftment of the donor cells by transiently
disrupting the endothelial barrier [11]. In addition, HIR allows the
engrafted cells to respond more efficiently to mitotic stimuli, such
as partial hepatectomy or expression of hepatic growth factor
(HGF), than the host hepatocytes. This leads to extensive
repopulation of the liver with complete correction of the metabolic
defect in the uridinediphosphoglucuronate glucuronosyltransferase
1A1 (ugt1a1)-deficient Gunn rat model of Crigler-Najjar syn-
drome type 1 (CN1) [16] and a mouse model of primary
hyperoxaluria type 1 (PH1) [17].
Despite the encouraging results in the rodent models, whole
liver HIR has not been tested as a preparative regimen in clinic
trials because the risk of RILD may be greater in primates,
including humans. However, recent clinical studies using confor-
mal HIR have shown that partial irradiation of the liver markedly
reduces the occurrence of RILD and allows far greater doses of
radiation to be delivered safely [18,19]. Therefore, we wanted to
test the hypothesis that preparative HIR of one or two selected
liver lobes should result in a sufficient wild-type donor cell mass for
correction of an inherited metabolic liver disease.
Initially, for the convenience of identification of the donor cells,
we transplanted hepatocytes from F344 rats into congeneic
DPPIV2 recipients by injection into the splenic pulp [15]. To
verify the regiospecificity of liver repopulation, we irradiated one
half of the median lobe, followed by mitotic stimulation by
injecting an adenovector expressing HGF (Ad-HGF) intravenously
[20]. To determine whether repopulation of one or two of the five
liver lobes is sufficient to correct hyperbilirubinemia in Gunn rats,
wildtype hepatocytes from congeneic Wistar rats (Roman High
Avoidance, RHA strain) were transplanted after regional HIR to
the median lobe (30% of liver mass) or median plus left anterior
lobes (60% of liver mass). Mitotic stimulation was provided by
injection of Ad-HGF. Our results demonstrate for the first time
that repopulating a single liver lobe by regional HIR is sufficient to
cure hyperbilirubinemia in Gunn rats. Combined with mitotic
stimulation, conformal HIR permits marked liver repopulation by
transplanted hepatocytes, thereby correcting hyperbilirubinemia,
as seen after whole liver HIR.
Materials and Methods
Animals
Male, 250–300 g wildtype Fisher 344 (F344) rats were
purchased from Taconic Farms (German Town, NY). Wildtype
Wistar-RHA rats, congeneic Gunn rats and DPPIV- deficient
F344 rats were bred and maintained on normal rat chow diet and
the climate-controlled facility of the Institute for Animal Studies at
the Albert Einstein College of Medicine in a 12-hr light/dark
cycle. This study was approved by the Institutional Animial Care
and Use Committee of the Albert Einstein College of Medicine.
Viral Vector
An adenoviral vector expressing human HGF was generated by
the Cell Culture and Genetic Engineering Core of the Marion
Bessin Liver Research Center of the Albert Einstein College of
Medicine [21].
Regional Hepatic irradiation
Regional HIR in rats was performed as reported with some
modifications [15]. Briefly, the liver was exposed by midline
incision and all liver lobes and other abdominal organs were
covered by 2 mm-thick lead shields, except the region targeted to
be irradiated. We have previously conducted a dose escalation
(15–50 Gy) study of preparative HIR and demonstrated 50 Gy
was optimal in achieving.80% repopulation of Gunn rat livers by
transplanted hepatocytes [16]. We, therefore, administered a HIR
dose of 50 Gy selectively to the exposed half of the median lobe in
DPPIV2 rats (n = 3), and the whole median lobe (n = 6) or median
and left lobe (n = 8) in Gunn rats, using a Philips orthovoltage unit
operating at 320 kVP, 5 mA, and 0.5 mm copper filtration at
200cGy/min. Control Gunn rats (n = 4) underwent laparotomy,
but no HIR was delivered. In our study we had to deliver intra-
operative HIR to rat livers in order to spatially confine the
irradiation dose to specific liver lobes because of the use of
orthovoltage animal irradiator and the small volume of liver in
rats. However clinical translation of our preparative HIR
technique could be easily achieved in humans via external beam
RT using modern 3D conformal techniques. Indeed, fractionated
external beam RT has been used as a preparative regimen for
hepatocyte transplantation in F344 rats using a clinical linear
accelerator [22,23].
Hepatocyte isolation and transplantation
Donor hepatocytes were isolated from DPPIV+ wildtype F344
rats or ugt1a1+ wildtype Wistar-RHA rats by an in situ two-step
collagenase perfusion procedure [24]. Male DPPIV2 Fisher rats
and Gunn rats (180–200 g body weight) that had received regional
HIR served as recipients for congeneic normal F344 and Wistar-
RHA rat hepatocytes, respectively. Twenty-four hours after
conformal HIR, 107 hepatocytes were transplanted by intrasplenic
injection as described [16]. Ad-HGF (1011 particles) was injected
via the tail vein 24 hours after hepatocyte transplantation [20].
Control rats received sham surgery (no HIR), Ad-HGF injection
and hepatocyte transplantation.
Histochemical staining for DPPIV activity
The median lobe subjected to conformal HIR was separated
from other liver lobes and snap-frozen in pre-cooled 2-methylbu-
tane at 280uC. Five-micron thick cryostat liver sections were fixed
for 5 min in cold 95% ethanol/5% glacial acetic acid (99:1vol/vol)
on ice and followed by a 5 min wash in cold 95% ethanol on ice.
The sections were then air-dried and stained for DPPIV
histochemistry as previously described [25].
Immunofluorescent staining for ugt1a1 expression
Five-micron frozen sections of liver tissues were fixed with ice-
cold acetone/methanol for 45 minutes. Then the sections were
incubated for 60 minutes at room temperature with the primary
antibody (rabbit polyclonal antibody raised against a 31-mer
polypeptide corresponding to the unique amino-terminal domain
of rat ugt1a1) at 1:50 dilution after blocking with donkey serum.
The sections were washed thrice with phosphate-buffered saline
(PBS) and incubated for 45 minutes at room temperature with the
secondary antibody, Cy3-conjugated donkey anti-rabbit IgG
(H+L) at 1:200 dilution (Jackson ImmunoResearch Laboratories,
Inc.). After extensive washing, the cover slips were mounted onto
the slides with Vectashield (Vector Laboratories) and imaged using
a Nikon Eclipse TE 2000-S fluorescent microscope.
Measurement of ugt1a1 protein content in different
lobes
Liver fragments (100–150 mg) from each lobe were homoge-
nized in a glass-Teflon motorized homogenizer and protein
concentrations were determined (Bio-Rad protein assay). The
proteins (100 mg/lane) were subjected to electrophoresis on 5%–
7.5% polyacrylamide gradient SDS/glycine gel. Following elec-
trophoresis, proteins were transferred onto a polyvinylidene
Regiospecific Repopulation of the Liver
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difluoride membranes (Bio-Rad). The membranes were blocked
with 5% fat-free milk powder in PBS followed by incubation with
the rabbit antiserum directed against the rat ugt1a1 amino-
terminal domain. After washing with PBS, the membranes were
incubated with a horseradish peroxidase–conjugated goat anti-
rabbit IgG (Sigma) and developed using an enhanced chemilumi-
nescence reagent (ECL Plus; Amersham, Arlington Heights, IL).
Measurement of serum bilirubin levels
Approximately 0.4 ml of blood was collected from the rat tail
vein before any experimental procedure (pretransplant) and at
various time points after transplantation under isoflurane anes-
thesia, and serum bilirubin levels were determined using an
automated clinical microchemistry system (Bayer Chem One;
Bayer Corp., Tarrytown, NY).
Analysis of bilirubin species excreted in bile
Bile samples were collected from the bile ducts of the Gunn rats
after completion of serial blood collection, and were analyzed by
reverse-phase high-performance liquid chromatography as de-
scribed [16].
Assay for ugt1a1 activity toward bilirubin
Ugt1a1 enzyme activity in the rat livers was analyzed as
described previously [26].
Statistical analysis
Repopulation of donor cells was assessed by counting the
number of ugt1a1-stained donor hepatocytes in host liver lobes
after ugt1a1 immunohistochemistry. Sampling regions were
chosen at random for digital acquisition for data quantitation in
a blinded fashion. A total of 20 fields at 2006magnification, each
from irradiated and non-irradiated liver lobes of three rats per
treatment group were used for each data point. The serum
bilirubin values were expressed as the mean 6 standard deviation
(SD) and the ugt1a1 enzyme activity was expressed as percent of
ugt1a1 activity in the wildtype Wistar RHA rat liver in order to
estimate the extent of repopulation of host liver by donor
hepatocytes. Statistical differences between two groups were
determined by a two-sided Student t test. P values less than 0.05
were considered statistically significant.
Results
Targeted HIR enabled regiospecific liver repopulation in
DPPIV2 recipients
To determine the effect of targeted HIR to the liver, DPPIV+
F344 hepatocytes were transplanted into congeneic DPPIV2 rat
livers that had been subjected to preparative HIR of one half of
the median lobe only. Three months after transplantation, 30–
60% of the irradiated region of the median lobe was selectively
Figure 1. Regiospecific liver repopulation in DPPIV2 recipients by donor DPPIV+ hepatocytes following conformal HIR of one half of
the median lobe. All liver lobes, except one half of the median lobe were shielded from HIR. Three months after hepatocyte transplantation, liver
sections were stained histochemically for DPPIV activity. A region at the junction of the irradiated and non-irradiated regions of the median lobe is
shown. Panel a. Low power view showing clusters of DPPIV-positive donor hepatocytes (red, white arrow) in the upper part of the section that had
received preparative HIR, and the absence of such clusters in the lower part of the section that had been shielded from HIR. Panel b. High power view
showing a donor hepatocyte cluster. The black bars indicate 100 mm.
doi:10.1371/journal.pone.0046775.g001
Figure 2. Conformal HIR followed by hepatocyte transplanta-
tion ameliorates bilirubin levels in a hyperbilirubinemia
model. The control group of Gunn rats received Ad-HGF followed by
hepatocyte transplantation without HIR (triangles, n = 4). One experi-
mental group received Ad-HGF and preparative median lobe HIR (1/3 of
liver, diamonds, n = 6) before hepatocyte transplantation. Another
experimental group received Ad-HGF and preparative HIR of the
median plus left lobe (2/3 of liver, circles, n = 8) before hepatocytes
transplantation.
doi:10.1371/journal.pone.0046775.g002
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replaced by DPPIV+ donor hepatocytes, indicating massive
proliferation of the donor cells. In contrast, the non-irradiated
half of the lobe contained only individual DPPIV+ donor
hepatocytes, indicating lack of significant donor cell proliferation
(Figure 1).
Serum bilirubin levels in Gunn rat recipients
In order to demonstrate the functionality of the repopulated
donor hepatocytes in irradiated host liver, we transplanted
congeneic ugt1a1-proficient Wistar hepatocytes in jaundiced
ugt1a1-deficient Gunn rats, following regiospecific preparative
HIR. The effect of liver replacement in Gunn rat recipients by
transplanted hepatocytes is shown in Figure 2. In the group
receiving HIR of the median lobe (30% of the liver mass) only,
mean serum bilirubin levels declined from pretransplantation
values of 5.1760.78 mg/dl to 0.9660.30 mg/dl (mean 6 SD) in
8 weeks after hepatocyte transplantation (p,0.0001), and
remained close to that level throughout the study. In the group
of Gunn rats that received median and left lobes irradiation (60%
of the liver mass), serum bilirubin levels declined more rapidly
than in the group receiving HIR of the median lobe only, so that
the mean values were significantly lower in this group at 4-weeks.
However, serum bilirubin concentrations in both groups stabilized
at similar levels (1.1260.22 mg/dl) in 8 weeks. In both HIR
groups, the serum bilirubin levels were significantly lower than in
the group receiving laparotomy and Ad-HGF, but no HIR, at all
time points beyond 4 weeks after transplantation (p,0.0001).
Analysis of bilirubin species excreted in bile
Bile duct cannulae were placed, as previously described [16], at
the end of the observation period in all Gunn rat recipients in
order to examine the bilirubin species in the bile of recipient
animals. Representative HPLC analyses of pigments excreted in
the bile collected from untreated Gunn rats (Fig. 3A), congeneic
wildtype Wistar-RHA rats (Fig. 3B) and Gunn rats receiving the
various treatments are shown in Figure 3. As expected, the bile of
untreated Gunn rats contained only unconjugated bilirubin, no
bilirubin glucuronides (Figure 3A), whereas bile of the Wistar-
Figure 3. HPLC profile of bilirubin species excreted in bile. (A) The bile of untreated Gunn rats contained some unconjugated bilirubin, but no
bilirubin glucuronides. (B) Bile of the wildtype Wistar-RHA donors contained predominantly bilirubin diglucuronide and monoglucuronide and a very
small amount of unconjugated bilirubin. (C) Three months after hepatocyte transplantation following HIR to 1/3 of liver, the pigment profile of bile in
transplant-recipient Gunn rats became similar to that of the normal Wistar rats, except that there was still a significant amount of unconjugated
bilirubin in the bile. (D) Three months after hepatocyte transplantation following HIR to 2/3 of liver, the pigment profile of bile in transplant-recipient
Gunn rats became similar to that of Gunn rats received HIR to 1/3 of liver.
doi:10.1371/journal.pone.0046775.g003
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RHA rats contained predominantly bilirubin diglucuronide and
monoglucuronide, and only a small amount of unconjugated
bilirubin (Figure 3B). In the groups receiving hepatocyte trans-
plantation after preparative HIR targeted to the median lobe
(Figure 3C) or the median plus left lobe (Figure 3D) of the liver, the
pigment profile of bile became similar to that of the wildtype
Wistar-RHA donor rats, except that there was still a significant
amount of unconjugated bilirubin in the recipient Gunn rat bile.
Immunofluorescent staining for ugt1a1 in different liver
lobes
Liver repopulation was examined three months after hepatocyte
transplantation and conformal HIR to the median liver lobe, by
immunofluorescent staining for ugt1a1. As expected, transplanted
hepatocytes selectively repopulated the median lobe. Based on
examination of 20 fields at 2006 magnification, approximately
20% (range 18–22%) of the irradiated lobe was replaced by
ugt1a1+ donor hepatocytes, whereas the unirradiated left, and
right lobes contained only small occasional ugt1a1+ hepatocyte
clusters. When both the median and the left lobe were irradiated,
18–30% hepatocytes in each lobe were repopulated by the
transplanted cells. The caudate lobe, which receives the least
scattered radiation because of its anatomical location, contained
only individual engrafted donor hepatocytes (Figure 4).
Ugt1a1 content of the different lobes
Three months after hepatocyte transplantation and preparative
HIR to the median and left lobe, 52-kd ugt1a1-immunoreactive
bands were observed in all four lobes of Gunn rat livers. However,
the ugt1a1 content in the irradiated median and left lobe was
much higher than that of unirradiated right and caudate lobe
(Figure 5).
Ugt1a1 activity toward bilirubin
Following transplantation, ugt1a1 activity in the liver homog-
enates was assayed with bilirubin as the acceptor substrate. In
Gunn rat livers that received regiospecific HIR prior to hepatocyte
transplantation, ugt1a1 activity in irradiated median and left lobes
was about 25–40% of the activity found in control Wistar-RHA
rat livers (2.660.14 mmol/g liver per hour). These values were
significantly higher than in the unirradiated lobes of Gunn rat
livers, which were less than 5% of the activity in livers of Wistar-
RHA rats (P,0.01). Similarly, ugt1a1 activity in the median lobe
of Gunn rats that had received preparative HIR to that lobe only
was about 21–24% of the activity in wildtype RHA rats, and was
significantly higher than the activity in the unirradiated left, right,
and caudate lobes. The ugt1a1 activity was undetectable in
untreated Gunn rats (Figure 6).
Discussion
Crigler-Najjar syndrome type 1 (CN1) is a potentially lethal
autosomal recessive disorder characterized by life long non-
hemolytic unconjugated hyperbilirubinemia. The disorder results
from a deficiency of ugt1a1 activity, which is critical for
glucuronidation and excretion of bilirubin [27]. Although
phototherapy and plasmapheresis treatment have extended the
life expectancy of patients with this disorder, liver transplantation
is still the only definitive treatment [27]. As liver transplantation is
a formidable surgical procedure, hepatocyte transplantation is
being explored as a minimally invasive alternative to whole organ
transplantation in the management of several liver-based meta-
bolic disorders and liver failure [1–7,27]. Because a fraction of the
normal hepatic enzyme content is often sufficient to support
metabolic function, we and others have proposed that transplan-
tation of isolated hepatocytes might cure several inherited liver-
based metabolic disorders. After extensive preclinical research in
animal models, we performed hepatocyte transplantation in a
patient with CN1, which resulted in a significant reduction of
serum bilirubin levels [1]. However, the levels were not low
enough to obviate the need for phototherapy. Following our
report, several groups confirmed that hepatocyte transplantation
successfully, but partially, ameliorated hyperbilirubinemia in CN1
patients [1,4,28,29]. Thus, it was clear that the number of
hepatocytes that could be safely engrafted into the liver of CN1
patients was not sufficient to achieve complete cure of the disease.
We then performed further preclinical studies to achieve
proliferation of the engrafted hepatocytes within the liver. Host
hepatocytes in CN1 patients, as in most other liver-based inherited
metabolic disorders, have normal proliferative capacity. As the
liver to body weight ratio is maintained within a tight limit by
strong physiological mechanisms, the engrafted wildtype cells can
proliferate only by replacing the host hepatocytes. Massive hepatic
repopulation has been achieved by genetic, chemical and physical
means to limit the mitotic capacity of the host [12,14,30,31].
Under these circumstances, mitotic stimuli after hepatocyte
Figure 4. Immunofluorescent staining for ugt1a1 in different
liver lobes. Three months after hepatocyte transplantation following
HIR to median lobe (ML), 20% of the irradiated median lobe was
replaced by donor hepatocytes, whereas the unirradiated left (LL), right
(RL) and caudate (CL) lobes contained only small ugt1a1+ hepatocyte
clusters.
doi:10.1371/journal.pone.0046775.g004
Figure 5. Western blot for ugt1a1 in the Gunn rat liver
following HIR to 2/3 of liver and hepatocyte transplantation.
Three months after hepatocyte transplantation, ugt1a1 protein was
demonstrated in the irradiated and unirradiated liver lobes of Gunn rats
by western blot analysis. However, the ugt1a1 content in irradiated
lobes was much higher than that of unirradiated lobes. RHA, Wistar-
RHA rat liver; ML, median lobe; LL, left lobe;, RL, right lobe; CL, caudate
lobe.
doi:10.1371/journal.pone.0046775.g005
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transplantation can cause massive preferential proliferation of the
host cells, which competitively repopulate the host liver [13].
As the chemical methods used to inhibit host hepatocyte
proliferation are not readily translatable to clinical use, we
investigated preparative HIR for achieving liver repopulation by
transplanted hepatocytes. These studies showed that whole liver
HIR in combination with a mitotic stimulus, such as partial
hepatectomy or HGF expression, results in massive liver repop-
ulation and complete correction of the metabolic defect in Gunn
rats [16], as well as in a mouse model of PH1 (hepatic
alanine:glyoxylate aminotransferase deficiency) [17,20]. In addi-
tion, we have found that preparative HIR enhances engraftment
in non-human primates [11]. A major hurdle to the application of
this promising technology to clinical hepatocyte transplantation is
concern about inducing RILD. Whole liver irradiation in
primates, including humans, is associated with RILD that differs
in severity and pathological characteristics from HIR-induced
RILD in rodents. Therefore, it is critical to determine the tolerable
dose of HIR in humans, and, if possible devise strategies to prevent
clinical RILD. In humans, irradiation targeted to parts of the liver
is tolerated much better than whole liver irradiation. It has been
reported that therapeutic irradiation of one third of the liver
volume in humans is tolerated up to doses as high as 90 Gy
without manifestation of RILD [18,19]. In fact, when radiation
was targeted to ,25% of the liver volume, RILD did not occur at
any irradiation dose tested.
In contrast to the treatment of the liver by drugs or chemicals,
modern conformal irradiation technology permits HIR delivery to
precisely targeted regions. This should permit repopulation of
specific regions of the liver, keeping the remaining liver
unperturbed. To take advantage of this unique characteristic of
irradiation, it would be important to estimate the volume of the
liver that must be repopulated to achieve a cure of a metabolic
liver disease. Our results in the DPPIV2 recipient rats demon-
strate that the area of the liver to be repopulated can be precisely
mapped by targeting preparative HIR to that area. Percent
repopulation of the liver was somewhat lower in the Gunn rat
recipients than in the DPPIV- rats, which could have resulted from
the strain difference. Nevertheless, we show that as little as 20%
repopulation of 30% of the liver volume in the Gunn rat recipients
was sufficient to correct hyperbilirubinemia. Repopulation of twice
that volume reduced serum bilirubin levels more rapidly, but
ultimately the long-term effect was similar with both HIR groups.
Excretion of bilirubin glucuronides in the bile confirmed the
function of the repopulating donor cells in vivo. In addition, there
was a significant unconjugated bilirubin peak in the bile of the
transplant recipients. A similar pattern is also found in human
subjects with Gilbert syndrome, who have a partial deficiency of
bilirubin glucuronidation [32]. This finding is consistent with the
fact that the ugt1A1 deficiency was partially, but not completely
normalized. In terms of potential clinical application, it should be
noted that the therapeutic objective in patients with CN1 is to
reduce serum bilirubin concentrations to safe levels, which can be
clearly achieved by partial restitution of hepatic bilirubin
glucuronidation.
Although we used an adenoviral vector to express HGF, for
clinical application the mitotic stimulation will need to be achieved
by alternative methods. Humanized activating antibodies to c-met,
which have a much longer half-life in the circulation are being
evaluated toward this goal in preclinical studies.
In conclusion, we have shown for the first time that targeted
irradiation of liver lobes can be used to precisely delineate a
fraction of the liver volume to be repopulated by transplanted
hepatocytes. Partial repopulation of one third of the liver volume
using this method cured hyperbilirubinemia in the Gunn rat
model of CN1. Our finding is highly relevant to potential clinical
application of preparative HIR for hepatocyte transplantation
because irradiation of a limited liver volume is tolerated much
better than whole liver irradiation in the clinic. Modern conformal
irradiation techniques can precisely delineate regions of the liver to
Figure 6. Ugt1a1 activity toward bilirubin in Gunn rats that received conformal HIR before hepatocyte transplantation. Ugt1a1
activities in liver homogenates of different recipient groups as in Figure 2 are shown (means6SD) as percent of the activity in the liver of Wistar-RHA
rats (2.6 mmol/g liver per hour).
doi:10.1371/journal.pone.0046775.g006
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be irradiated, thereby avoiding the development of RILD. In
combination with newer approaches to providing mitotic stimu-
lation to the engrafted hepatocytes, regiospecific HIR could pave
the way for a safe and highly effective hepatocyte transplantation-
mediated treatment regimen for a large number of liver-based
inherited metabolic diseases.
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